eligibility_summary
Inclusion: Adults ≥18 with advanced/metastatic solid tumors lacking standard options, measurable disease, fresh tissue, ECOG 0–1, life expectancy ≥12 wks, contraception/nonpregnant. Exclusion: Prior B7‑H3, recent anti‑cancer therapy/RT/surgery, active CNS disease, prohibited CYP/P‑gp/BCRP or QT‑prolonging meds, BRCA/ATM, organ/marrow dysfunction, major CV disease, uncontrolled diabetes/hypertension, recent/active bleeding, thrombosis or infection, immunosuppression, advanced cirrhosis, HS‑20093 allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: HS-20093, a fully humanized IgG1 antibody–drug conjugate (ADC), IV 8 mg/kg Q3W monotherapy. Mechanism: specifically binds B7‑H3 (CD276), an immune checkpoint broadly overexpressed on solid tumors, upon binding, the ADC is internalized and releases a cytotoxic payload to kill tumor cells, as an IgG1, it may also engage Fc‑mediated effector functions. Targets: B7‑H3–positive tumor cells (including mCRPC) and the B7‑H3–mediated immune‑evasion axis in the tumor microenvironment. Trial: Phase 2, open‑label, single‑arm study in mCRPC and other advanced solid tumors after failure/intolerance of standard therapies.